Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Fosaprepitant for Prevention of CINV in Moderately Emetogenic Chemotherapy
NCT01594749Phase 3Completed
- Sponsor
- Merck & Co.
- Start
- Sep 2012
- Primary completion
- Nov 2014
- Modality
- Small Molecules
01
Overview
A Phase 3 trial of fosaprepitant in chemotherapy-induced nausea and vomiting (CINV), sponsored by Merck & Co.. Started Sep 2012; status: completed.
02
Drugs
fosaprepitant
03
Conditions
chemotherapy-induced nausea and vomiting (CINV)
Beyond the preview
Go deeper on NCT01594749.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT01594749.